SG Americas Securities LLC Has $151,000 Holdings in Supernus Pharmaceuticals Inc (SUPN)

SG Americas Securities LLC decreased its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 54.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,306 shares of the specialty pharmaceutical company’s stock after selling 4,018 shares during the quarter. SG Americas Securities LLC’s holdings in Supernus Pharmaceuticals were worth $151,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SUPN. Wells Fargo & Company MN raised its position in shares of Supernus Pharmaceuticals by 18.6% in the first quarter. Wells Fargo & Company MN now owns 896,110 shares of the specialty pharmaceutical company’s stock valued at $41,041,000 after purchasing an additional 140,688 shares during the period. BlackRock Inc. raised its position in shares of Supernus Pharmaceuticals by 1.8% in the fourth quarter. BlackRock Inc. now owns 6,902,230 shares of the specialty pharmaceutical company’s stock valued at $275,054,000 after purchasing an additional 120,394 shares during the period. Capital Fund Management S.A. bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $3,621,000. Cortina Asset Management LLC raised its position in shares of Supernus Pharmaceuticals by 77.7% in the fourth quarter. Cortina Asset Management LLC now owns 166,321 shares of the specialty pharmaceutical company’s stock valued at $6,628,000 after purchasing an additional 72,721 shares during the period. Finally, Daiwa Securities Group Inc. bought a new position in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $3,159,000. 97.59% of the stock is currently owned by institutional investors.

In other news, VP Victor Vaughn sold 60,000 shares of the business’s stock in a transaction on Thursday, April 5th. The shares were sold at an average price of $45.33, for a total value of $2,719,800.00. Following the sale, the vice president now owns 24,344 shares in the company, valued at approximately $1,103,513.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 67,132 shares of the business’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $53.11, for a total transaction of $3,565,380.52. Following the completion of the sale, the vice president now owns 32,500 shares in the company, valued at approximately $1,726,075. The disclosure for this sale can be found here. Insiders sold a total of 152,850 shares of company stock worth $7,596,524 in the last 90 days. 6.20% of the stock is owned by corporate insiders.



Shares of Supernus Pharmaceuticals opened at $53.75 on Friday, Marketbeat.com reports. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of 42.66 and a beta of 1.10. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.74 and a current ratio of 4.90. Supernus Pharmaceuticals Inc has a 52-week low of $33.30 and a 52-week high of $59.05.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.16. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%. The firm had revenue of $90.43 million for the quarter, compared to analyst estimates of $85.26 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The business’s revenue for the quarter was up 57.1% on a year-over-year basis. analysts expect that Supernus Pharmaceuticals Inc will post 1.9 EPS for the current fiscal year.

SUPN has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. BidaskClub lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Stifel Nicolaus boosted their target price on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, May 25th. Finally, Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $52.55.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply